Immunterápia

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (opens new window)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

Forrás‎: N Engl J Med 2017;376(9):836-47.

Azonosító‎: PubMed 28249141

DOI‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (opens new window)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (opens new window)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

Forrás‎: N Engl J Med 2014;371(16):1507-17.

Azonosító‎: PubMed 25317870

DOI‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (opens new window)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (opens new window)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

Forrás‎: N Engl J Med 2018;378(5):439-48.

Azonosító‎: PubMed 29385370

DOI‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (opens new window)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (opens new window)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

Forrás‎: Cancer 2013;119(22):4036-43.

Azonosító‎: PubMed 24006085

DOI‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (opens new window)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (opens new window)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

Forrás‎: Clin Cancer Res 2016;22(8):1951-7.

Azonosító‎: PubMed 26644412

DOI‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (opens new window)

ONKOLÓGIA (GYERMEKGYÓGYÁSZAT)

Immunterápia

magyar

Immunterápia

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (opens new window)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (opens new window)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (opens new window)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (opens new window)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (opens new window)

Kórházi összekötő bizottság (köb)

Orvosi információs gyűjtemény

Videók

Immunterápia

Válassz nyelvet

Megosztás